Age >60NCT07260903
Can Photobiomodulation Improve Balance and Cognition in Individuals Over 60: a Pilot Feasibility Placebo Randomized Controlled Trial.
A study testing Photobiomodulation in people with Age >60, run by University of Central Lancashire at 1 site in United Kingdom.
Trial summary
As people age, changes in balance and memory can make daily life more difficult and increase the risk of falls. Falls are one of the main causes of injury, hospitalization and loss of independence in older adults, while even mild declines in memory and concentration can reduce confidence, social participation and… Read more about this study
- Who is it for?
- Ages 60 to 80 yearsHealthy volunteers can take part
- Conditions the study is for
- Age >60
- What is being tested?
- Photobiomodulation
- Type of treatment
- Medical device
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 60 participants
- Where
- 1 siteUnited Kingdom
- Study dates
- 1 Jun 2025to 10 Jul 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 60 to 80 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Aged from 60-80 years
- Ability to complete written questionnaires independently
- Able to provide informed consent
Who cannot join
- Current or past history of head injury
- Use of medications acting on the central nervous system
- Active skin conditions on the forehead or scalp
- Ongoing brain stimulation therapy
- History of migraines
- Sensitive skin, allergies
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United Kingdom1 site, 1 recruiting
- Recruiting
University of Central Lancashire
Preston, Lancashire, PR4 0PE
Jonathan Sinclair, DSc, 07875651533, jksinclair@lancashire.ac.uk
About this study
As people age, changes in balance and memory can make daily life more difficult and increase the risk of falls. Falls are one of the main causes of injury, hospitalization and loss of independence in older adults, while even mild declines in memory and concentration can reduce confidence, social participation and overall quality of life. Therefore, safe, affordable, and practical ways to help older adults remain steady on their feet and mentally sharp are urgently needed.
The aim of this project is therefore to conduct a pilot feasibility randomized controlled trial to examine whether regular home-based photobiomodulation can improve balance and cognitive function in adults aged over 60. If successful, this research could help shape future strategies for preventing falls, enhancing wellbeing and maintaining independence in older people.
- Conditions
- Age >60
- Being tested
- Photobiomodulation, Sham 8-weeks photobiomodulation
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
PhotobiomodulationDevice
8-weeks photobiomodulation
Sham 8-weeks photobiomodulationOther
The sham device will follow the same protocol but without active light emission.
| Study group | Role | What they receive |
|---|---|---|
| Sham photobiomodulation | Sham comparator | 8-weeks sham photobiomodulation.
The sham device will follow the same protocol but without active light emission. Receives: Other: Sham 8-weeks photobiomodulation |
| Photobiomodulation | Experimental | 8-weeks photobiomodulation
Twenty-four-minute photobiomodulation stimulation (twelve minutes at 670 nm followed by twelve minutes at 810 nm). Three times per week for 8-weeks. Receives: Device: Photobiomodulation |
What is being measured
The primary outcome is the main question the study is designed to answer.
n-1-back (deviation)
The n-1-back (deviation) task is a working memory test where participants respond when the current stimulus differs from the one presented n-1 trials earlier.
Measured: Baseline
n-1-back (deviation)
The n-1-back (deviation) task is a working memory test where participants respond when the current stimulus differs from the one presented n-1 trials earlier.
Measured: 1 hour
n-1-back (deviation)
The n-1-back (deviation) task is a working memory test where participants respond when the current stimulus differs from the one presented n-1 trials earlier.
Measured: 8-weeks
Secondary outcomes (51)
n-2-back (deviation)
The n-2-back (deviation) task is a working memory test where participants respond when the current stimulus differs from the one presented n-2 trials earlier.
Measured: Baseline
n-2-back (deviation)
The n-2-back (deviation) task is a working memory test where participants respond when the current stimulus differs from the one presented n-2 trials earlier.
Measured: 1 hour
n-2-back (deviation)
The n-2-back (deviation) task is a working memory test where participants respond when the current stimulus differs from the one presented n-2 trials earlier.
Measured: 8-weeks
n-1-back (post-deviation)
The n-1-back (post-deviation) task assesses working memory performance on the trial immediately following a deviation from the stimulus presented n-1 trials earlier.
Measured: Baseline
n-1-back (post-deviation)
The n-1-back (post-deviation) task assesses working memory performance on the trial immediately following a deviation from the stimulus presented n-1 trials earlier.
Measured: 1 hour
n-1-back (post-deviation)
The n-1-back (post-deviation) task assesses working memory performance on the trial immediately following a deviation from the stimulus presented n-1 trials earlier.
Measured: 8-weeks
n-2-back (post-deviation)
The n-2-back (post-deviation) task assesses working memory performance on the trial immediately following a deviation from the stimulus presented n-2 trials earlier.
Measured: Baseline
n-2-back (post-deviation)
The n-2-back (post-deviation) task assesses working memory performance on the trial immediately following a deviation from the stimulus presented n-2 trials earlier.
Measured: 1 hour
n-2-back (post-deviation)
The n-2-back (post-deviation) task assesses working memory performance on the trial immediately following a deviation from the stimulus presented n-2 trials earlier.
Measured: 8-weeks
n-1-back (post-target)
The n-1-back (post-target) task assesses working memory performance on the trial immediately following a target that matched the stimulus presented n-1 trials earlier.
Measured: Baseline
n-1-back (post-target)
The n-1-back (post-target) task assesses working memory performance on the trial immediately following a target that matched the stimulus presented n-1 trials earlier.
Measured: 1 hour
n-1-back (post-target)
The n-1-back (post-target) task assesses working memory performance on the trial immediately following a target that matched the stimulus presented n-1 trials earlier.
Measured: 8-weeks
n-2-back (post-target)
he n-2-back (post-target) task assesses working memory performance on the trial immediately following a target that matched the stimulus presented n-2 trials earlier.
Measured: Baseline
n-2-back (post-target)
he n-2-back (post-target) task assesses working memory performance on the trial immediately following a target that matched the stimulus presented n-2 trials earlier.
Measured: 1 hour
n-2-back (post-target)
he n-2-back (post-target) task assesses working memory performance on the trial immediately following a target that matched the stimulus presented n-2 trials earlier.
Measured: 8-weeks
n-1-back (load)
The n-1-back (load) condition measures working memory performance under the cognitive demand of tracking stimuli 1 trial back.
Measured: Baseline
n-1-back (load)
The n-1-back (load) condition measures working memory performance under the cognitive demand of tracking stimuli 1 trial back.
Measured: 1 hour
n-1-back (load)
The n-1-back (load) condition measures working memory performance under the cognitive demand of tracking stimuli 1 trial back.
Measured: 8-weeks
n-2-back (post-load)
The n-2-back (post-load) condition assesses working memory performance on the trial immediately following a high cognitive load in the n-2-back task.
Measured: Baseline
n-2-back (post-load)
The n-2-back (post-load) condition assesses working memory performance on the trial immediately following a high cognitive load in the n-2-back task.
Measured: 1 hour
n-2-back (post-load)
The n-2-back (post-load) condition assesses working memory performance on the trial immediately following a high cognitive load in the n-2-back task.
Measured: 8-weeks
Coop-Wonka chart
The Coop-Wonka chart is a six item questionnaire with a 1-5 scoring system for each thus the chart has a maximum score of 30 which indicates the lowest possible psychological Wellbeing.
Measured: Baseline
Coop-Wonka chart
The Coop-Wonka chart is a six item questionnaire with a 1-5 scoring system for each thus the chart has a maximum score of 30 which indicates the lowest possible psychological Wellbeing.
Measured: 1 hour
Coop-Wonka chart
The Coop-Wonka chart is a six item questionnaire with a 1-5 scoring system for each thus the chart has a maximum score of 30 which indicates the lowest possible psychological Wellbeing.
Measured: 8-weeks
Beck Depression Inventory
Psychological wellbeing - the Beck Depression Inventory is a 21 questionnaire with questions that range in scoring from 0-3, thus the maximum score is 63 which is the highest depression score possible.
Measured: Baseline
Beck Depression Inventory
Psychological wellbeing - the Beck Depression Inventory is a 21 questionnaire with questions that range in scoring from 0-3, thus the maximum score is 63 which is the highest depression score possible.
Measured: 1 hour
Beck Depression Inventory
Psychological wellbeing - the Beck Depression Inventory is a 21 questionnaire with questions that range in scoring from 0-3, thus the maximum score is 63 which is the highest depression score possible.
Measured: 8-weeks
Pittsburgh Sleep Quality Index
The Pittsburgh Sleep Quality index, is a questionnaire that consists of 19 self-rated questions, grouped into 7 components. Each component is scored separately, weighted equally on a 0 - 3 scale and the scores of the 7 components are then added to give a global score, which has a range of 0 - 21 with higher scores indicating worse sleep quality.
Measured: Baseline
Pittsburgh Sleep Quality Index
The Pittsburgh Sleep Quality index, is a questionnaire that consists of 19 self-rated questions, grouped into 7 components. Each component is scored separately, weighted equally on a 0 - 3 scale and the scores of the 7 components are then added to give a global score, which has a range of 0 - 21 with higher scores indicating worse sleep quality.
Measured: 1 hour
Pittsburgh Sleep Quality Index
The Pittsburgh Sleep Quality index, is a questionnaire that consists of 19 self-rated questions, grouped into 7 components. Each component is scored separately, weighted equally on a 0 - 3 scale and the scores of the 7 components are then added to give a global score, which has a range of 0 - 21 with higher scores indicating worse sleep quality.
Measured: 8-weeks
State Trait Anxiety Inventory
The state trait anxiety inventory is a 40 item questionnaire with each question having a 1-4 score system, thus the maximum score is 80 which indicates the highest level of anxiety.
Measured: Baseline
State Trait Anxiety Inventory
The state trait anxiety inventory is a 40 item questionnaire with each question having a 1-4 score system, thus the maximum score is 80 which indicates the highest level of anxiety.
Measured: 1 hour
State Trait Anxiety Inventory
The state trait anxiety inventory is a 40 item questionnaire with each question having a 1-4 score system, thus the maximum score is 80 which indicates the highest level of anxiety.
Measured: 8-weeks
Insomnia Severity Index
The Insomnia Severity Index is a brief instrument designed to assess the severity of both nighttime and daytime components of insomnia. The Insomnia Severity Index is a 7-item self-report questionnaire yielding a total score ranging from 0 to 28.
Measured: Baseline
Insomnia Severity Index
The Insomnia Severity Index is a brief instrument designed to assess the severity of both nighttime and daytime components of insomnia. The Insomnia Severity Index is a 7-item self-report questionnaire yielding a total score ranging from 0 to 28.
Measured: 1 hour
Insomnia Severity Index
The Insomnia Severity Index is a brief instrument designed to assess the severity of both nighttime and daytime components of insomnia. The Insomnia Severity Index is a 7-item self-report questionnaire yielding a total score ranging from 0 to 28.
Measured: 8-weeks
Epworth Sleepiness Scale
The Epworth Sleepiness Scale is a self-administered questionnaire with 8 questions. Respondents are asked to rate, on a 4-point scale (0-3) with a maximum score of 24.
Measured: Baseline
Epworth Sleepiness Scale
The Epworth Sleepiness Scale is a self-administered questionnaire with 8 questions. Respondents are asked to rate, on a 4-point scale (0-3) with a maximum score of 24.
Measured: 1 hour
Epworth Sleepiness Scale
The Epworth Sleepiness Scale is a self-administered questionnaire with 8 questions. Respondents are asked to rate, on a 4-point scale (0-3) with a maximum score of 24.
Measured: 8-weeks
Everyday Memory Errors Questionnaire
The Everyday Memory Errors Questionnaire is a brief self-report instrument designed to assess the frequency of memory lapses in daily life. It consists of multiple items that yield a total score reflecting the extent of everyday memory difficulties.
Measured: Baseline
Everyday Memory Errors Questionnaire
The Everyday Memory Errors Questionnaire is a brief self-report instrument designed to assess the frequency of memory lapses in daily life. It consists of multiple items that yield a total score reflecting the extent of everyday memory difficulties.
Measured: 1 hour
Everyday Memory Errors Questionnaire
The Everyday Memory Errors Questionnaire is a brief self-report instrument designed to assess the frequency of memory lapses in daily life. It consists of multiple items that yield a total score reflecting the extent of everyday memory difficulties.
Measured: 8-weeks
Falls Efficacy
The Falls Efficacy Scale is a brief self-report instrument designed to assess confidence in performing daily activities without falling. It consists of multiple items that yield a total score reflecting fear of falling and perceived fall-related self-efficacy.
Measured: Baseline
Falls Efficacy
The Falls Efficacy Scale is a brief self-report instrument designed to assess confidence in performing daily activities without falling. It consists of multiple items that yield a total score reflecting fear of falling and perceived fall-related self-efficacy.
Measured: 1 hour
Falls Efficacy
The Falls Efficacy Scale is a brief self-report instrument designed to assess confidence in performing daily activities without falling. It consists of multiple items that yield a total score reflecting fear of falling and perceived fall-related self-efficacy.
Measured: 8-weeks
Anterior-posterior balance
The maximum anterior-posterior displacement of the centre of pressure during a two-minute balance task.
Measured: Baseline
Anterior-posterior balance
The maximum anterior-posterior displacement of the centre of pressure during a two-minute balance task.
Measured: 1 hour
Anterior-posterior balance
The maximum anterior-posterior displacement of the centre of pressure during a two-minute balance task.
Measured: 8-weeks
Medio-lateral balance
The maximum medio-lateral displacement of the centre of pressure during a two-minute balance task.
Measured: Baseline
Medio-lateral balance
The maximum medio-lateral displacement of the centre of pressure during a two-minute balance task.
Measured: 1 hour
Medio-lateral balance
The maximum medio-lateral displacement of the centre of pressure during a two-minute balance task.
Measured: 8-weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted3 Dec 2025
- Study start1 Jun 2025
- Primary completion1 May 2027 (estimated)
- Study completion10 Jul 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Age >60Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 60 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University of Central Lancashire
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Jonathan Sinclair, University of Central Lancashire
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07260903
- Sponsor's protocol ID
- PMB balance and cognition
- Status last verified
- Nov 2025
- First submitted
- 21 Nov 2025
- Last updated
- 3 Dec 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 3 Dec 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Can Photobiomodulation Improve Balance and Cognition in Individuals Over 60: a Pilot Feasibility Placebo Randomized Controlled Trial.
- ClinicalTrials.gov ID
- NCT07260903
- Acronym / sponsor ID
- PMB balance and cognition
- Conditions
- Age >60
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 60 participants (estimated)
- Lead sponsor
- University of Central LancashireUniversity, hospital or other
- Study start
- 1 Jun 2025 (actual)
- Primary completion
- 1 May 2027 (estimated)
- Study completion
- 10 Jul 2027 (estimated)
- First posted
- 3 Dec 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
As people age, changes in balance and memory can make daily life more difficult and increase the risk of falls. Falls are one of the main causes of injury, hospitalization and loss of independence in older adults, while even mild declines in memory and concentration can reduce confidence, social participation and overall quality of life. Therefore, safe, affordable, and practical ways to help older adults remain steady on their feet and mentally sharp are urgently needed.
The aim of this project is therefore to conduct a pilot feasibility randomized controlled trial to examine whether regular home-based photobiomodulation can improve balance and cognitive function in adults aged over 60. If successful, this research could help shape future strategies for preventing falls, enhancing wellbeing and maintaining independence in older people.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, investigator)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Sham photobiomodulation | Sham comparator | Other: Sham 8-weeks photobiomodulation8-weeks sham photobiomodulation. The sham device will follow the same protocol but without active light emission. |
| Photobiomodulation | Experimental | Device: Photobiomodulation8-weeks photobiomodulation Twenty-four-minute photobiomodulation stimulation (twelve minutes at 670 nm followed by twelve minutes at 810 nm). Three times per week for 8-weeks. |
Who may qualify
- Ages
- 60 to 80 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- Aged from 60-80 years
- Ability to complete written questionnaires independently
- Able to provide informed consent
Key exclusion criteria (6 listed)
- Current or past history of head injury
- Use of medications acting on the central nervous system
- Active skin conditions on the forehead or scalp
- Ongoing brain stimulation therapy
- History of migraines
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Photobiomodulation8-weeks photobiomodulation | Device | Photobiomodulation |
| Sham 8-weeks photobiomodulationThe sham device will follow the same protocol but without active light emission. | Other | Sham photobiomodulation |
Primary outcome
n-1-back (deviation)
Time frame: Baseline
The n-1-back (deviation) task is a working memory test where participants respond when the current stimulus differs from the one presented n-1 trials earlier.
n-1-back (deviation)
Time frame: 1 hour
The n-1-back (deviation) task is a working memory test where participants respond when the current stimulus differs from the one presented n-1 trials earlier.
n-1-back (deviation)
Time frame: 8-weeks
The n-1-back (deviation) task is a working memory test where participants respond when the current stimulus differs from the one presented n-1 trials earlier.
51 secondary outcomes
n-2-back (deviation)
Time frame: Baseline
n-2-back (deviation)
Time frame: 1 hour
n-2-back (deviation)
Time frame: 8-weeks
n-1-back (post-deviation)
Time frame: Baseline
n-1-back (post-deviation)
Time frame: 1 hour
n-1-back (post-deviation)
Time frame: 8-weeks
n-2-back (post-deviation)
Time frame: Baseline
n-2-back (post-deviation)
Time frame: 1 hour
n-2-back (post-deviation)
Time frame: 8-weeks
n-1-back (post-target)
Time frame: Baseline
n-1-back (post-target)
Time frame: 1 hour
n-1-back (post-target)
Time frame: 8-weeks
n-2-back (post-target)
Time frame: Baseline
n-2-back (post-target)
Time frame: 1 hour
n-2-back (post-target)
Time frame: 8-weeks
n-1-back (load)
Time frame: Baseline
n-1-back (load)
Time frame: 1 hour
n-1-back (load)
Time frame: 8-weeks
n-2-back (post-load)
Time frame: Baseline
n-2-back (post-load)
Time frame: 1 hour
n-2-back (post-load)
Time frame: 8-weeks
Coop-Wonka chart
Time frame: Baseline
Coop-Wonka chart
Time frame: 1 hour
Coop-Wonka chart
Time frame: 8-weeks
Beck Depression Inventory
Time frame: Baseline
Beck Depression Inventory
Time frame: 1 hour
Beck Depression Inventory
Time frame: 8-weeks
Pittsburgh Sleep Quality Index
Time frame: Baseline
Pittsburgh Sleep Quality Index
Time frame: 1 hour
Pittsburgh Sleep Quality Index
Time frame: 8-weeks
State Trait Anxiety Inventory
Time frame: Baseline
State Trait Anxiety Inventory
Time frame: 1 hour
State Trait Anxiety Inventory
Time frame: 8-weeks
Insomnia Severity Index
Time frame: Baseline
Insomnia Severity Index
Time frame: 1 hour
Insomnia Severity Index
Time frame: 8-weeks
Epworth Sleepiness Scale
Time frame: Baseline
Epworth Sleepiness Scale
Time frame: 1 hour
Epworth Sleepiness Scale
Time frame: 8-weeks
Everyday Memory Errors Questionnaire
Time frame: Baseline
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 3 Dec 2025.
- Individual participant dataSharing planned: No
Related trials for Age >60
RecruitingPhase 2
Comparing Different Treatment Lengths for Venetoclax in Older People With Newly Diagnosed Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)
Acute Myeloid Leukemia
Active, not recruitingPhase 2
Siltuximab to Decrease Symptom Burden After Autologous Stem Cell Transplantation for Patients With Multiple Myeloma and AL Amyloidosis
Multiple Myeloma, AL Amyloidosis
Active, not recruitingPhase 1
A Phase 1 Study to Evaluate JCXH-108, an mRNA-based Vaccine Against RSV
Respiratory Syncytial Virus (RSV), Infectious Disease
Not yet recruitingPhase 3
A Study to Evaluate Efficacy, Immunogenicity and Safety of a Recombinant Respiratory Syncytial Virus Vaccine in Older Adults Aged 60 Years and Older
Respiratory Syncytial Virus (RSV), Respiratory Syncytial Virus (RSV) Infection
Not yet recruiting
Effects of Cannabidiol on Memory and Attention in Adults Aged 60-70: A Pilot Study
Healthy Aging, Cognition
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Photobiomodulation in people with Age >60, run by University of Central Lancashire at 1 site in United Kingdom.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 3 Dec 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Jonathan Sinclair, DSc (07875651533, jksinclair@lancashire.ac.uk), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
n-1-back (deviation) (time frame: Baseline). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 Dec 2025.